Beginning in 1974, cancer research on the MIT campus was organized by the Center for Cancer Research (CCR), which held the distinction of a NCI designated Cancer Center since its inception. In 2008, the CCR was renamed the David H. Koch Institute for Integrative Cancer Research (Kl) at MIT in recognition of a major expansion of the MIT's commitment to inter-disciplinary cancer research as well as a significant donation by Mr. Koch. In launching the Kl, the outstanding tradition of cancer science represented by the MIT CCR has been joined by a new focus on cancer-relevant engineering. Kl Investigators, who are drawn from multiple departments in the MIT Schools of Science and Engineering, will study cancer in many ways, using highly collaborative and integrative approaches with a clearly defined mission to apply advanced science and new technologies in the fight against cancer. A state-of-the-art building to house the Kl is currently under construction to be completed in late 2010. The Kl building will house approximately 25 Center members at capacity. An additional 20 member of this Center have laboratories located in other MIT Departments. Due to expansion of the Kl faculty and expanded focus on inter-disciplinary cancer research, we have increased from three Programs to four and reorganized each Program. The Programs are: 1 Molecular Genetics and Immunology;2 Animal Models and Genetics;3 Cell and Systems Biology;4 Engineering Science and Technology. In addition, each Program will be overseen by co-leaders to draw on the strengths of our faculty in science and engineering. Respectively, Phillip Sharp and Dane Wittrup, Tyler Jacks and Angelika Amon, Richard Hynes and Michael Yaffe, and, Robert Langer and Sangeeta Bhatia lead the four Programs. Each program is organized around common interests of the members and overlapping long-range goals. There is extensive intra-programmatic interaction among the members of these programs and many examples of inter-programmatic interaction as well. Of the 43 members listed in this CCSG application, 24 will be located the Koch Institute building at opening. The others are located in the Koch Biology Building (5), the Whitehead Institute (7), the Division of Biological Engineering (2), the Broad Institute (2), the Department of Chemistry (2), and the Center for Environmental Health Sciences (1). The Koch Institute has been organized to apply a broad range of tools and systems in biological sciences, engineering and the physical sciences to advance our understanding of cancer development, progression and response to therapy. This research also holds great potential for new discoveries for improved cancer treatment, detection and monitoring.

Public Health Relevance

The Koch Institute has been organized to apply a broad range of tools and systems in biological sciences, engineering and the physical sciences to advance our understanding of cancer development, progression and response to therapy. This research also holds great potential for new discoveries for improved cancer treatment, detection and monitoring.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014051-40
Application #
8145315
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-06-17
Project End
2015-04-30
Budget Start
2011-05-01
Budget End
2012-04-30
Support Year
40
Fiscal Year
2011
Total Cost
$3,854,331
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Internal Medicine/Medicine
Type
Schools of Arts and Sciences
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Lannagan, Tamsin R M; Lee, Young K; Wang, Tongtong et al. (2018) Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis. Gut :
Filbin, Mariella G; Tirosh, Itay; Hovestadt, Volker et al. (2018) Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science 360:331-335
Roper, Jatin; Tammela, Tuomas; Akkad, Adam et al. (2018) Colonoscopy-based colorectal cancer modeling in mice with CRISPR-Cas9 genome editing and organoid transplantation. Nat Protoc 13:217-234
Suzuki, Hiroshi I; Spengler, Ryan M; Grigelioniene, Giedre et al. (2018) Deconvolution of seed and RNA-binding protein crosstalk in RNAi-based functional genomics. Nat Genet 50:657-661
McKenney, Anna Sophia; Lau, Allison N; Somasundara, Amritha Varshini Hanasoge et al. (2018) JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. J Clin Invest 128:789-804
Richardson, Christopher E R; Cunden, Lisa S; Butty, Vincent L et al. (2018) A Method for Selective Depletion of Zn(II) Ions from Complex Biological Media and Evaluation of Cellular Consequences of Zn(II) Deficiency. J Am Chem Soc 140:2413-2416
Choudhury, Atish D; Werner, Lillian; Francini, Edoardo et al. (2018) Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight 3:
Chen, Pan-Yu; Muzumdar, Mandar Deepak; Dorans, Kimberly Judith et al. (2018) Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. Cancer Res 78:985-1002
Wong, Madeline Y; Chen, Kenny; Antonopoulos, Aristotelis et al. (2018) XBP1s activation can globally remodel N-glycan structure distribution patterns. Proc Natl Acad Sci U S A 115:E10089-E10098
Viswanathan, Srinivas R; Nogueira, Marina F; Buss, Colin G et al. (2018) Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nat Genet 50:937-943

Showing the most recent 10 out of 904 publications